The Consumer Healthcare Products Association released the following statement in response to the Trump Administration’s “Buy American” Executive Order (EO) for essential pharmaceuticals.
More than nine in ten Americans feel anxious about their finances amid the COVID-19 pandemic. Healthcare bills were noted as one of the top ten stressors.
The results of nearly all recent observational studies of patients from around the world diagnosed with COVID-19 show no association between exposure to NSAIDs (including ibuprofen) and worsening clinical outcomes.
CHPA is rebranding its identity for the first time in 20 years. The rebranding effort has resulted in a new logo, tagline, and brand narrative following the addition of consumer medical devices to its scope of representation.
CHPA, its educational foundation, and member companies are empowering consumers to practice responsible self-care, providing resources to help respond to this pandemic. We’re guided by these core principles.
There is currently no clinical data indicating that dextromethorphan has a pro-viral effect in people with COVID-19 infection. The study results published in Nature are experimental, preliminary, and not conclusive.
The U.S. dietary supplement industry commends FDA for taking action to protect consumers by calling out marketers who make illegal and unsubstantiated drug claims related to COVID-19.
While the “essential workforce” list is solely advisory in nature, it provides much-needed guidance to state and local governments as they proceed with their own “stay at home” orders across the country. It is important to make this list as precise as possible with few vagueries that can be left to interpretation.
